{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:48:17Z","timestamp":1786711697643,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are reported to reduce body fat in patients with type 2 diabetes mellitus (T2DM), and SGLT2i-induced weight reduction may help improve comorbid nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the potential benefit of SGLT2is over other oral antidiabetic drugs (OADs) in patients with T2DM-associated NAFLD. We enrolled real-world Korean patients with T2DM-associated NAFLD in whom initial metformin therapy had been modified by stepwise addition of OAD(s) due to insufficient glucose control. Propensity score (PS) matching was used for the comparison of changes in clinical and biochemical parameters to balance potential covariates. Among the 765 enrolled patients, 663 patients received additional OADs other than SGLT2i and 102 patients received SGLT2i therapy. PS matching selected 150 and 100 patients from the control and the SGLT2i group, respectively. The SGLT2i group lost more weight than the control group at 6 months (mean \u20131.3 kg <jats:italic>vs.<\/jats:italic> 0.0\u00a0kg; <jats:italic>P<\/jats:italic> &amp;lt; 0.001). Alanine aminotransferase (ALT) levels also decreased more in the SGLT2i group at 3 (\u201311 U\/L <jats:italic>vs.<\/jats:italic> \u20131 U\/L), 6 (\u201312 U\/L <jats:italic>vs.<\/jats:italic> \u20131 U\/L), and 12 months (\u201314 U\/L <jats:italic>vs.<\/jats:italic> \u20132 U\/L) (all <jats:italic>P<\/jats:italic> &amp;lt; 0.05). Addition of SGLT2is was an independent predictor of ALT improvement in a multivariate logistic regression model (odds ratio 1.91; <jats:italic>P<\/jats:italic> = 0.016). Compared with other OADs, addition of SGLT2is was more effective in weight reduction and ALT improvement in patients with T2DM and comorbid NAFLD.<\/jats:p>","DOI":"10.3389\/fendo.2021.613389","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T09:25:07Z","timestamp":1623317107000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Won","family":"Euh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4093\/dmj.2019.0011","article-title":"Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis","volume":"43","author":"Lee","year":"2019","journal-title":"Diabetes Metab J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to Diabetes Mellitus, Cardiovascular Disease or Cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-Alcoholic Fatty Liver Disease and Diabetes","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metabolism"},{"key":"B4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis","volume":"1","author":"Li","year":"2013","journal-title":"BioMed Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-Analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e4947","DOI":"10.1097\/MD.0000000000004947","article-title":"Thiazolidinediones for Nonalcoholic Steatohepatitis: A Meta-Analysis of Randomized Clinical Trials","volume":"95","author":"He","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. Placebo for Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Easl-Easd-Easo Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","volume":"64","author":"European Association for the Study of The","year":"2016","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin Reduces Fat Mass Without Affecting Muscle Mass in Type 2 Diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.05.017","article-title":"Dapagliflozin Significantly Reduced Liver Fat Accumulation Associated With a Decrease in Abdominal Subcutaneous Fat in Patients With Inadequately Controlled Type 2 Diabetes Mellitus","volume":"142","author":"Kurinami","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of Luseogliflozin on Hepatic Fat Content in Type 2 Diabetes Patients With Non-Alcoholic Fatty Liver Disease: A Prospective, Single-Arm Trial (LEAD Trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1569","article-title":"The Sglt2 Inhibitor Dapagliflozin Reduces Liver Fat But Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12834","article-title":"Effect of Sodium Glucose Cotransporter 2 Inhibitor on Liver Function Tests in Japanese Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the Effects of Dapagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Hepatic Steatosis and Fibrosis Using Transient Elastography in Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of Dapagliflozin and N-3 Carboxylic Acids on Non-Alcoholic Fatty Liver Disease in People With Type 2 Diabetes: A Double-Blind Randomised Placebo-Controlled Study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","article-title":"Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis","volume":"16","author":"Ajmera","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4258\/hir.2012.18.2.145","article-title":"Seoul National University Bundang Hospital\u2019s Electronic System for Total Care","volume":"18","author":"Yoo","year":"2012","journal-title":"Healthc Inform Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35354","article-title":"The Utility of Radiological Imaging in Nonalcoholic Fatty Liver Disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic Evaluation of Nonalcoholic Fatty Liver Disease","volume":"20","author":"Lee","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic Steatosis Index: A Simple Screening Tool Reflecting Nonalcoholic Fatty Liver Disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12980","article-title":"Effects of Canagliflozin on Body Composition and Hepatic Fat Content in Type 2 Diabetes Patients With Non-Alcoholic Fatty Liver Disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin Improves Liver Fat Deposition Compared to Metformin in Type 2 Diabetes Patients With Non-Alcoholic Fatty Liver Disease: A Prospective Randomized Controlled Pilot Study","volume":"20","author":"Shibuya","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.3.387","article-title":"Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease","volume":"33","author":"Choi","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive Biomarkers in NAFLD and NASH - Current Progress and Future Promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00086.2017","article-title":"Dapagliflozin Slows the Progression of the Renal and Liver Fibrosis Associated With Type 2 Diabetes","volume":"313","author":"Tang","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (An SGLT2 Inhibitor), Alone or in Combination With Linagliptin (A DPP-4 Inhibitor), Prevents Steatohepatitis in a Novel Mouse Model of Non-Alcoholic Steatohepatitis and Diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol Metab Syndr"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13304","article-title":"Impact of Sodium Glucose Cotransporter 2 Inhibitor on Histological Features and Glucose Metabolism of Non-Alcoholic Fatty Liver Disease Complicated by Diabetes Mellitus","volume":"49","author":"Akuta","year":"2019","journal-title":"Hepatol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The Improvement of the Hepatic Histological Findings in a Patient With Non-Alcoholic Steatohepatitis With Type 2 Diabetes After the Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-019-01018-1","article-title":"Long-Term Luseogliflozin Therapy Improves Histological Activity of Non-Alcoholic Steatohepatitis Accompanied by Type 2 Diabetes Mellitus","volume":"13","author":"Fujimori","year":"2020","journal-title":"Clin J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020","volume":"43","author":"American Diabetes","year":"2020","journal-title":"Diabetes Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4093\/dmj.2019.0137","article-title":"K.D.A. 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea","volume":"43","author":"Kim","year":"2019","journal-title":"Diabetes Metab J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.09.005","article-title":"Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complications and Cardiovascular Disease","volume":"44","author":"Bonnet","year":"2018","journal-title":"Diabetes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 Selective Inhibitor Ipragliflozin on Hyperglycemia, Hyperlipidemia, Hepatic Steatosis, Oxidative Stress, Inflammation, and Obesity in Type 2 Diabetic Mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.08.107","article-title":"Mechanistic Link Between Nonalcoholic Fatty Liver Disease and Cardiometabolic Disorders","volume":"201","author":"Lim","year":"2015","journal-title":"Int J Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/obr.12820","article-title":"Crosstalk Between Nonalcoholic Fatty Liver Disease and Cardiometabolic Syndrome","volume":"20","author":"Lim","year":"2019","journal-title":"Obes Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links Between Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2018.03.013","article-title":"Clinical Implications of Current Cardiovascular Outcome Trials With Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors","volume":"272","author":"Lim","year":"2018","journal-title":"Atherosclerosis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12226","article-title":"Predictive Value of ALT Levels for non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001284","article-title":"The Role of Noninvasive Tests for Differentiating NASH From NAFL and Diagnosing Advanced Fibrosis Among Patients With NAFLD","volume":"54","author":"Balakrishnan","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and Changes in Serum Alanine Aminotransferase Levels in Patients With Non-Alcoholic Steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.019","article-title":"Report on the AASLD\/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD","volume":"71","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dom.13926","article-title":"Propensity Score Methods in Real-World Epidemiology: A Practical Guide for First-Time Users","volume":"22","author":"Loke","year":"2020","journal-title":"Diabetes Obes Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.613389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T09:25:10Z","timestamp":1623317110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.613389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":49,"alternative-id":["10.3389\/fendo.2021.613389"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.613389","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"article-number":"613389"}}